NovaBay Pharmaceuticals Inc. (AMEX:NBY) finished Wednesday with a subtraction of $0.0 to close at $0.12, an upside of 0.49 percent. An average of 2,095,220 shares of common stock have been traded in the last five days. There was a fall of -$0.0334 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 979,695 shares traded, while the 50-day average volume stands at 822,416.
NBY stock has decreased by -50.64% in the last month. The company shares reached their 1-month lowest point of $0.1150 on 09/21/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $0.12 and a high of $0.77 in 52 weeks. It has reached a new high 2 times so far this year and lost -67.42% or -$0.2539 in price. In spite of this, the price is down -84.06% from the 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
8 days have passed since NovaBay Pharmaceuticals Inc. (NBY) last reported insider trading activity. Kunin Jeffrey, who is President, DERMAdoctor, LLC, most recently acquired $291,368 shares at $0.16 per share on Sep 14. In this transaction, the insider spent $46,094. Chief Product Officer, Kunin Audrey, disposed of 291,368 shares at a price of $0.16 on Sep 14. The insider now owns more than $46,094 worth of shares.
NovaBay Pharmaceuticals Inc. (NBY) stock’s beta is 2.82. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 0.68, the price-to-book (PB) ratio at 0.42.
The quick ratio of NovaBay Pharmaceuticals Inc. for the three months ended March 30 was 1.50, and the current ratio was 2.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending March 30. Its gross profit as reported stood at $5.64 million compared to revenue of $8.42 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, NovaBay Pharmaceuticals Inc.’s return on assets was -26.40%.
In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$2.16 million in the quarter, while revenues were grew 13.89%. The analyst consensus anticipated NovaBay Pharmaceuticals Inc.’s latest quarter earnings to come in at -$0.03 per share, but it turned out to be -$0.05, a -66.70% surprise. For the quarter, EBITDA amounted to -$2.03 million. Shareholders own equity worth $53.51 million.
From a technical analysis perspective, let’s take a brief look at NovaBay Pharmaceuticals Inc. (NBY) price momentum. RSI 9-day as of the close on 21 September was 10.60%, suggesting the stock is oversold, with historical volatility in this time frame at 49.67%.
As of today, NBY’s price is $0.1318 -21.40% or -$0.0334 from its 5-day moving average. NBY is currently trading -49.17% lower than its 20-day SMA and -48.05% lower than its 100-day SMA. However, the stock’s current price level is -55.38% below the SMA50 and -72.11% below the SMA200.
The stochastic %K and %D were 5.89% and 6.97%, respectively, and the average true range (ATR) was 0.0217. With the 14-day stochastic at 6.16% and the average true range at 0.0229, the RSI (14) stands at 18.11%. The stock has reached -0.0267 on the 9-day MACD Oscillator while the 14-day reading was at -0.0512.
Ladenburg Thalmann launched coverage on NovaBay Pharmaceuticals Inc. (AMEX: NBY) in its analyst report released on September 18, 2019. The firm assigned the stock a Buy rating. The consensus rating for NovaBay Pharmaceuticals Inc. (NBY) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell NBY, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 2 others rate it as a “buy”.
What is NBY’s price target for the next 12 months?
Analysts predict a range of price targets between $1.85 and $3.75, with a median target of $2.80. Taking a look at these predictions, the average price target given by analysts for NovaBay Pharmaceuticals Inc. (NBY) stock is $2.80.